Please Direct All Correspondence to Customer Number **20995**

**TRANSMITTAL LETTER**  
**INFORMATION DISCLOSURE STATEMENT**


Applicant : Andersson, et al.  
App. No : 10/601,070  
Filed : June 20, 2003  
For : N-SUBSTITUTED PIPERIDINE  
DERIVATIVES AS SEROTONIN  
RECEPTOR AGENTS  
Examiner : Charanjit Aulakh  
Art Unit : 1625

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

November 17, 2006

(Date)

  
Daniel Hart, Reg. No. 40,637

**Mail Stop Amendment**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:


Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement and PTO/SB/08 equivalent listing references for consideration:
  - (X) Listing eighty-one (81) references.
  - (X) Enclosing fifty-nine (59) references.
- (X) A check in the amount of \$180 to cover the above fee is enclosed.
- (X) Return prepaid postcard.

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.



Daniel Hart  
Registration No. 40,637  
Attorney of Record  
Customer No. 20,995  
(619) 235-8550



Docket No.: ACADIA.020A

Customer No. 20,995

### INFORMATION DISCLOSURE STATEMENT

Applicant : Andersson, et al.  
App. No : 10/601,070  
Filed : June 20, 2003  
For : N-SUBSTITUTED PIPERIDINE  
DERIVATIVES AS SEROTONIN  
RECEPTOR AGENTS  
Examiner : Charanjit Aulakh  
Art Unit : 1625

#### CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

November 17, 2006

(Date)

Daniel Hart, Reg. No. 40,637

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing eighty-one (81) references to be considered by the Examiner. Also enclosed are fifty-nine (59) foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed before the mailing date of a final action and before the mailing of a Notice of Allowance. This Statement is accompanied by the fees set forth in 37 C.F.R. § 1.17(p). The Commissioner is hereby authorized to charge any additional fees which may be required or to credit any overpayment to Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: Nov. 17, 2006


By: Daniel Hart

Daniel Hart  
Registration No. 40,637  
Attorney of Record  
Customer No. 20,995  
(619) 235-8550

12/04/2006 EAREGAY1 00000009 10601070

01 FC:1806

180.00 OP



<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Multiple sheets used when necessary)	Application No.	10/601,070
	Filing Date	June 20, 2003
	First Named Inventor	Carl-Magnus Andersson
	Art Unit	1625
SHEET 1 OF 4	Examiner	Charanjit Aulakh
	Attorney Docket No.	ACADIA.020A

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	1	4,332,804	06-01-1982	Clark	
	2	5,214,055	05-25-1993	Peglion, et al.	
	3	5,595,872	01-21-1997	Wetterau II, et al.	
	4	5,621,010	04-15-1997	Sueda, et al.	
	5	7,041,667	05-09-2006	Armour, et al.	
	6	7,115,634	10-03-2006	Thurieu, et al.	
	7	2004/0213816 A1	10-28-2004	Weiner, et al.	
	8	2005/0148018 A1	07-07-2005	Weiner, et al.	
	9	2005/0244862 A1	11-03-2005	Brann	
	10	2005/0256108 A1	11-17-2005	Schlienger	
	11	2006/0094758 A1	05-04-2006	Andersson, et al.	
	12	2006/0106063 A1	05-18-2006	Thygesen, et al.	
	13	2006/0111399 A1	05-25-2006	Thygesen, et al.	
	14	2006/0194778 A1	08-31-2006	Andersson, et al.	
	15	2006/0194834 A1	08-31-2006	Andersson, et al.	
	16	2006-0199794 A1	09-07-2006	Schlienger	
	17	2006-0199818 A1	09-07-2006	Andersson, et al.	
	18	2006-0199842 A1	09-07-2006	Weiner, et al.	
	19	2006-0205710 A1	09-14-2006	Schlienger, et al.	
	20	2006-0205722 A1	09-14-2006	Andersson, et al.	
	21	2006-0205781 A1	09-14-2006	Thygesen, et al.	
	22	2006-0205780 A1	09-14-2006	Thygesen, et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>1</sup>
	23	WO 98/44921 A1	10-15-1998	Merck & Co., Inc.		
	24	WO 03/057698 A2	07-17-2003	Acadia Pharmaceuticals, Inc.		
	25	WO 03/057698 A3	07-17-2003	Acadia Pharmaceuticals, Inc.		

Examiner Signature	Date Considered
--------------------	-----------------

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	Application No.	10/601,070
	Filing Date	June 20, 2003
	First Named Inventor	Carl-Magnus Andersson
	Art Unit	1625
(Multiple sheets used when necessary)	Examiner	Charanjit Aulakh
SHEET 2 OF 4	Attorney Docket No.	ACADIA.020A

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>1</sup>
	26	WO 03/062206 A2	07-31-2003	Arena Pharmaceuticals, Inc.		
	27	WO 03/062206 A3	07-31-2003	Arena Pharmaceuticals, Inc.		
	28	WO 03/070246 A1	08-28-2003	Pfizer Products Inc.		
	29	WO 2004/000808 A2	12-31-2003	Acadia Pharmaceuticals Inc.		
	30	WO 2004/000808 A3	12-31-2003	Acadia Pharmaceuticals Inc.		
	31	WO 2004/064738 A2	08-05-2004	Acadia Pharmaceuticals Inc.		
	32	WO 2004/064738 A3	08-05-2004	Acadia Pharmaceuticals Inc.		
	33	WO 2004/064753 A2	08-05-2004	Acadia Pharmaceuticals Inc.		
	34	WO 2005/063254 A2	07-14-2005	Acadia Pharmaceuticals Inc.		
	35	WO 2005/112927 A1	12-01-2005	Acadia Pharmaceuticals Inc.		
	36	WO 2006/036874 A1	04-06-2006	Acadia Pharmaceuticals Inc.		
	37	WO 2006/037043 A1	04-06-2006	Acadia Pharmaceuticals Inc.		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
	38	ADELL, et al. 2005. Strategies for producing faster acting antidepressants. <i>Drug Discovery Today</i> , 10(8):578-585.	
	39	AKIN, et al. 2004. Decreased serotonin 5-HT <sub>2A</sub> receptor-stimulated phosphoinositide signaling in fibroblasts from melancholic depressed patients. <i>Neuropsychopharmacology</i> , 29:2081-2087.	
	40	BLIER, et al. 2005. Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety. <i>J. Clin. Psychiatry</i> , 66(suppl 8):30-40.	
	41	CLIFTON, et al. 1982. Arylethanolamines Derived from Salicyclamide with $\alpha$ - and $\beta$ -Adrenoceptor Blocking Activities. Preparation of Labetalol, its Enantiomers, and Related Salicyclamides. <i>J. Med. Chem.</i> , 25:670-679.	
	42	GILLMAN, P. K. 2005. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. <i>British Journal of Anaesthesia</i> , 95(4):434-441.	
	43	KANAYAMA, et al. 2005. New treatment of lumbar disc herniation involving 5-hydroxytryptamine <sub>2A</sub> receptor inhibitor: A randomized controlled trial. <i>J. Neurosurg: Spine</i> , 2:441-446.	
	44	MAREK, et al. 2003. Synergistic action of 5-HT <sub>2A</sub> antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders. <i>Neuropsychopharmacology</i> , 28:402-412.	
	45	MAREK, et al. 2005. The selective 5-HT <sub>2A</sub> receptor antagonist M100907 enhances antidepressant-like behavioral effects of the SSRI fluoxetine. <i>Neuropsychopharmacology</i> , 30:2205-2215.	

Examiner Signature	Date Considered
--------------------	-----------------

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	Application No.	10/601,070
	Filing Date	June 20, 2003
	First Named Inventor	Carl-Magnus Andersson
	Art Unit	1625
(Multiple sheets used when necessary)	Examiner	Charanjit Aulakh
SHEET 3 OF 4	Attorney Docket No.	ACADIA.020A

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
	46	MÖHRLE, et al. 1990. Sodium mercury edetate dehydrogenation of N-aliphatic substituted 1,2,3,6-tetrahydropyridine derivatives. <i>Arch. Pharm. (Weinheim)</i> , 323:109-115.	
	47	MOULIGNIER, A. 1994. Récepteurs centraux de la sérotonine principaux aspects fondamentaux et fonctionnels application thérapeutiques. <i>Rev. Neurol.</i> , 150:3-15. (Abstract)	
	48	NIGAM, et al. 1957a. Studies with acetylenes. Part II. Some reactions of Grignard reagents with propargylic halides. Model linoleic and linolenic acid systems. <i>J. Chem Soc.</i> , pp. 3868-3873.	
	49	NIGAM, et al. 1957b. The conversion of fatty acids into aldehydes. <i>J. Chem. Soc.</i> , pp.3320-3321.	
	50	OGAWA, et al. 2005. Effects of R-102444 and its active metabolite R-96544, selective 5-HT <sub>2A</sub> receptor antagonists, on experimental acute and chronic pancreatitis: Additional evidence for possible involvement of 5-HT <sub>2A</sub> receptors in the development of experimental pancreatitis. <i>European Journal of Pharmacology</i> , 521:156-163.	
	51	PATEL, et al. 2004. The highly selective 5-hydroxytryptamine (5-HT) <sub>2A</sub> receptor antagonist, EMD 281014, significantly increases swimming and decreases immobility in male congenital learned helpless rats in the forced swim test. <i>Synapse</i> , 52:73-75.	
	52	PIERCE, et al. 1995. 5-hydroxytryptamine-induced synovial plasma extravasation is mediated via 5-hydroxytryptamine <sub>2A</sub> receptors on sympathetic efferent terminals. <i>The Journal of Pharmacology and Experimental Therapeutics</i> , 275(1):502-508.	
	53	STRYJER, et al. 2003. Treatment of neuroleptic-induced akathisia with the 5-HT <sub>2A</sub> antagonist trazodone. <i>Clinical Neuropharmacology</i> , 26(3):137-141.	
	54	Notice of Allowance and Fee(s) Due and Notice of Allowability dated May 15, 1997, from Application No. 08/273,669 filed July 12, 1994, now U.S. Pat. No. 5,707,798.	
	55	Office Action dated March 27, 1998, from Application No. 08/954,724 filed October 20, 1997, now U.S. Pat. No. 5,912,132.	
	56	Notice of Allowability and Issue Fee Transmittal dated September 4, 1998, from Application No. 08/954,724 filed October 20, 1997, now U.S. Pat. No. 5,912,132.	
	57	Office Action dated September 14, 1998, from Application No. 08/965,947 filed November 7, 1997, now U.S. Pat. No. 5,955,281.	
	58	Interview Summary dated November 17, 1998, from Application No. 08/965,947 filed November 7, 1997, now U.S. Pat. No. 5,955,281.	
	59	Office Action dated April 25, 2002, from Application No. 09/800,096 filed March 6, 2001, now U.S. Pat. No. 6,815,458.	
	60	Office Action dated January 21, 2003, from Application No. 09/800,096 filed March 6, 2001, now U.S. Pat. No. 6,815,458.	
	61	Office Action dated July 15, 2003, from Application No. 09/800,096 filed March 6, 2001, now U.S. Pat. No. 6,815,458.	
	62	Notice of Allowability dated December 8, 2003, from Application No. 09/800,096 filed March 6, 2001, now U.S. Pat. No. 6,815,458.	

Examiner Signature	Date Considered
<b>*Examiner:</b> Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	Application No.	10/601,070
	Filing Date	June 20, 2003
	First Named Inventor	Carl-Magnus Andersson
	Art Unit	1625
(Multiple sheets used when necessary)	Examiner	Charanjit Aulakh
SHEET 4 OF 4	Attorney Docket No.	ACADIA.020A

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
	63	Notice of Allowance and Fee(s) Due and Notice of Allowability dated December 5, 2003, from Application No. 10/409,782 filed April 7, 2003, now U.S. Pat. No. 6,756,393.	
	64	International Preliminary Examination Report dated March 18, 2003, for PCT/US01/07187.	
	65	Office Action dated February 28, 2001, from Application No. 09/413,626 filed October 6, 1999, now U.S. Pat. No. 6,358,698.	
	66	Notice of Allowance and Fee(s) Due and Notice of Allowability dated November 20, 2001, from Application No. 09/413,626 filed October 6, 1999, now U.S. Pat. No. 6,358,698.	
	67	Specification from Application No. 11/417,070 filed May 3, 2006.	
	68	Specification from Application No. 11/417,083 filed May 3, 2006.	
	69	Notice of Allowance and Fee(s) Due and Notice of Allowability dated February 11, 2005, from Application No. 10/329,719 filed December 23, 2002, now U.S. Pat. No. 6,911,452.	
	70	Written Opinion dated September 9, 2003, for PCT/US02/41476.	
	71	International Preliminary Examination Report dated January 15, 2004, for PCT/US02/41476.	
	72	Written Opinion for PCT/US03/19797 dated April 5, 2004.	
	73	Specification from Application No. 11/416,527 filed May 3, 2006.	
	74	Specification from Application No. 11/416,855 filed May 3, 2006.	
	75	International Search Report for PCT/US2004/001234 dated September 8, 2004.	
	76	International Written Opinion for PCT/US2004/001234 dated September 8, 2004.	
	77	International Preliminary Report on Patentability for PCT/US2004/001234 dated April 14, 2005.	
	78	Written Opinion of the International Searching Authority for PCT/US2005/034813 dated January 30, 2006.	
	79	Written Opinion of the International Searching Authority for PCT/US2005/034376 dated January 30, 2006.	
	80	Office Action dated June 26, 2006, from Application No. 11/154,083 filed June 16, 2005.	
	81	Office Action dated October 5, 2006, from Application No. 11/418,322 filed May 3, 2006.	

2862141:dmb  
082206

Examiner Signature	Date Considered
<p><b>*Examiner:</b> Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.